CLLKF Stock Chart & Stats
$1.55
$0.03(1.84%)
At close: 4:00 PM EDT
$1.55
$0.03(1.84%)
Day’s Range― - ―
52-Week Range$1.38 - $4.07
Previous CloseN/A
Volume500.00
Average Volume (3M)167.00
Market Cap
$106.88M
Enterprise Value$1.12K
Total Cash (Recent Filing)$744.30M
Total Debt (Recent Filing)$690.60M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 19, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.97
Shares Outstanding69,074,900
10 Day Avg. Volume250
30 Day Avg. Volume167
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$161.49M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Services RevenueBICO’s business model centers on instrument sales plus tied consumables, software and services. An expanding installed base drives recurring consumables and service revenue, improving revenue visibility and customer stickiness versus one-time equipment sales alone.
Improved Gross Margin And Positive Operating Cash FlowA material gross margin improvement alongside positive operating cash flow signals better unit economics and the ability to convert sales into cash. Sustained margins with cash generation support reinvestment in R&D, product support and scaling recurring revenue streams over the medium term.
Moderate Leverage Relative To EquityWith debt below equity and a moderate leverage profile, BICO has greater capacity to fund operations or absorb shocks than a highly leveraged peer. This structural buffer supports strategic flexibility for investment, partnerships or addressing working-capital needs over months.
Bears Say
Deep, Recurring LossesPersistently large net losses indicate the company has not translated improved gross margins into profitability. Continued negative margins erode retained earnings, constrain reinvestment, and raise risk that operational improvements may be insufficient to reach sustainable positive earnings.
Sharp Decline In Free Cash FlowA steep drop in free cash flow and historically inconsistent cash generation reduce runway for product development and commercialization. If FCF weakness persists, the company may need external financing, which could dilute shareholders or limit strategic choices over the medium term.
Eroding Equity Base Reduces FlexibilityA materially reduced equity base limits the firm’s capacity to absorb further losses or pursue investments without raising fresh capital. This structural weakening increases reliance on external funding and constrains strategic M&A, hiring, or expansion in the event performance falters.
BICO Group AB Class B News
CLLKF FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was $1.38 and its highest was $4.07 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is $106.88M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Aug 19, 2026 which is in 13 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Apr 29, 2026. The company reported -$0.164 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.058.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.07.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -$0.164 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went up 10.243%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in CLLKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
CLLKF Company Deck
CLLKF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.View all CLLKF earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.56% Other Institutional Investors
95.14% Public Companies and
Individual Investors